|
News
2009-09-18
Maxim Biomedical launched its new web site.
2009-07-01
Maxim Biomedical had a major restructure.
2009-01-25
ISO 13485:2004 approval.
2005-11-15
Maxim acquired Calypte Biomedical’s Cambridge Biotech HIV-1 Serum Western Blot Kit, Cambridge Biotech HIV-1 Urine Western Blot Kit and Calypte HIV-1 Urine EIA Kit and its GMP facility.
2005-05-16
PLEASANTON, Calif., May 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation announced today that in conjunction with its previously announced restructuring plan, it has entered into a manufacturing services and management agreement with Maxim Biomedical, Inc. According to the terms of the agreement, going forward, Maxim will manufacture, ship and perform quality control procedures for Calypte's urine EIA, serum Western Blot and urine Western Blot HIV in vitro diagnostic tests. The manufacturing services agreement will continue for a limited time until a definitive ...
2003-10-16
Calypte Biomedical Corporation (BULLETIN BOARD: CYPT) , the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced today that the Company has signed a multi-year agreement with LabOne, Inc., Lenexa, Kan., for the purchasing of Calypte diagnostic products. Calypte and LabOne have maintained a working relationship since 1996.
2003-08-26
Calypte Biomedical Corporation (BULLETIN BOARD: CYPT) , the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, announced that it has reached an agreement with WHO that additional evaluation of the Calypte HIV-1 Urine EIA screening tests and its Cmabrigde Biotech Urine Western Blot supplemental test is not required. In light of the successful results achieved in Phase 1 trials and the significant costs, and resources that would be required ...
2003-05-06
ALAMEDA, Calif.--(BUSINESS WIRE)--May 6, 2003
Calypte Biomedical Corporation (OTCBB:CALY) today announced that the FDA has just authorized the use of its Cambridge Biotech HIV-1 Western Blot serum/plasma test as an additional specific test to be used with serum or plasma specimens obtained from subjects found to be reactive using rapid HIV-1 tests.
2003-04-10
ALAMEDA, Calif.--(BUSINESS WIRE)--April 10, 2003
Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test, said today that its decision to establish a distribution relationship with Adaltis U.S. Inc. has opened up new markets for its Cambridge Biotech serum Western blot product, without negatively impacting the Company's direct customers.
2003-03-04
ALAMEDA, Calif.--(BUSINESS WIRE)--March 4, 2003
Calypte Biomedical Corporation (OTCBB:CALY), the developer and marketer of the only two FDA-approved HIV-1 antibody tests that can be used on urine samples, today announced receipt of U.S. Food and Drug Administration (FDA) approval to eliminate the lot release testing requirement for the company's Cambridge Biotech HIV-1 Urine Western Blot test. On the heels of the company's January 8, 2003 approval eliminating FDA lot release testing for its HIV-1 Urine EIA test,...
2001-06-27
ALAMEDA, Calif.--(BUSINESS WIRE)--June 27, 2001
Conversion of Regulatory Status Will Improve Production Efficiency and Reduce Production Costs Calypte Biomedical Corporation (Nasdaq: CALY) announced today that the United States Food and Drug Administration (FDA) has approved Calypte's premarket approval application (PMA) for the Cambridge Biotech(TM) HIV-1 Urine Western Blot.
2001-02-06
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 6, 2001
Calypte Biomedical Corporation (NASDAQ: CALY) announced today that beginning this month, Organon Teknika Corporation, a leader in the field of in vitro diagnostics, will distribute worldwide an HIV-1 Western Blot serum (blood) assay manufactured by Calypte Biomedical.
Organon Teknika will distribute the test non-exclusively under Calypte's Cambridge Biotech tradename. The long-term arrangement calls for minimum monthly shipments, significantly increasing Calypte's serum Western Blot ...
2000-05-20
ALAMEDA, Calif.--(BUSINESS WIRE)--May 10, 2000
Fast and Affordable Program Can Increase Testing and Reduce Anxious Waits for Patients
Calypte Biomedical Corporation (NASDAQ:CALY) announced today that its Sentinel(TM) testing service, the nation's first and only urine-based testing service dedicated exclusively to the detection of exposure to HIV-1, chlamydia, and gonorrhea sexually transmitted diseases (STDs), is now available throughout the United States.
2000-01-20
ALAMEDA, CA--(BUSINESS WIRE)--Jan. 24, 2000
Revolutionary Service Offers Fast, Affordable, Painless Testing Method for STDs
Calypte Biomedical Corporation (NASDAQ:CALY) announced today that it has entered into a collaboration with Wampole Laboratories, a division of Carter Wallace, Inc. (NYSE:CAR), and Clinical Reference Laboratory (CRL) to launch a new national urine-based testing service for HIV-1 antibody, chlamydia, and gonorrhea.
1999-11-18
ALAMEDA, Calif.--(BUSINESS WIRE)--November 18, 1999--
Calypte Biomedical Corporation (Nasdaq: CALY) announced today that the U.S. Food and Drug Administration (FDA) approved a "Day Assay" license supplement to its "Cambridge Biotech" Human Immunodeficiency Virus Type 1 (HIV-1) Western Blot test that confirms the presence of antibodies to HIV-1 in serum samples. The approval of the "Day Assay" format supplement means that Calypte Biomedical's "Cambridge Biotech" HIV-1 Western Blot assay can now be used in either a overnight or a day assay.
1999-09-16
ALAMEDA, Calif.--(BUSINESS WIRE)--Sept. 16, 1999--
Carter-Wallace to Market Calypte's Three FDA-Approved HIV-1 Tests to Hospitals, Public Health Facilities and Reference Laboratories
Calypte Biomedical Corporation (NASDAQ: CALY) announced today that it has signed a definitive distribution agreement which will give Carter-Wallace, Inc. (NYSE: CAR) the exclusive U.S. sales and marketing rights for Calypte's HIV products in the hospital, public health and reference lab markets. Distribution will be through Carter-Wallace's Wampole Laboratories ...
1998-11-24
BERKELEY, Calif.--(BW HealthWire)--Nov. 24, 1998--Calypte Biomedical Corporation (Nasdaq:CALY) today announced that it has entered into an agreement to acquire the assets relating to the Western blot product line for certain infectious diseases. The acquisition includes the urine-based and serum-based HIV-1 Western blot products, as well as a confirmatory test for Lyme Disease and Human T-Lymphotropic Virus (HTLV). Under the terms of the agreement, Calypte will acquire the assets from Cambridge Biotech Corporation, a wholly-owned subsidiary of bioMerieux, Inc., for $500,000 ...
1997-03-17
BERKELEY, Calif.--(BW HealthWire)--March 17, 1997--Calypte Biomedical Corp. (NASDAQ:CALY) announced today that it has completed the clinical trials requested by the U.S. FDA regarding the use of a urine-based Western blot for HIV-1 antibodies. The Western blot is intended to be used as a specific, supplemental test on urines which are repeatedly reactive using Calypte's Urine HIV-1 EIA screening test. The EIA, also distributed by Seradyn Inc. (Indianapolis, Ind.) under the Sentinel tradename, was licensed by the FDA in August 1996.
1996-01-09
Corporation today announced that the United States Bankruptcy Court for the District of Massachusetts (Western Division) has declared a non- exclusive patent license to be in effect between Institut Pasteur and Cambridge Biotech as of January 1, 1996, covering Cambridge's HIV-1 Western Blot test. Introduced in the U.S. in 1987, Cambridge Biotech's HIV-1 Western blot confirmatory test is used in the diagnosis of AIDS to confirm the results of less sensitive screening assays.
1990-09-13
CAMBRIDGE BIOSCIENCE AND BIOTECH RESEARCH LABORATORIES
BECOME CAMBRIDGE BIOTECH CORPORATION ON CLOSING OF MERGER
WORCESTER, Mass., Sept. 13 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX), announced the closing of the merger between the former Cambridge BioScience Corporation, based in Worcester, and Biotech Research Laboratories Inc. (NASDAQ: BTRL) of Rockville, Md. Shareholders of both companies approved the merger on Sept. 5. The effective date of both the merger and the corporate name change was Sept. 7.
|
